Exopharm Limited announces further progress and support from investors. Dr Jennifer King, based in the USA, joined the Exopharm board on 31st August 2021 and has made significant contributions to the company since that time. Dr King has provided sound advice in relation to partnering, testing and product activities.

Dr King has decided to resign from her role as a non-executive director of the Company. Mr. Clarke Barlow has consented to become a non-executive director of the company and will immediately fill the vacancy left by Dr King. Clarke is an experienced non-executive director.

Based in Perth, Clarke is a Financial Adviser and Capital Markets Specialist with over 20 years' experience in the Financial Services Industry in Australia and the United Kingdom. Clarke has experience in structuring, operations and risk management of institutional structured products in the United Kingdom and has been a Derivatives Manager, responsible for establishing and managing derivatives trading desks for several Australian based stockbroking firms. Clarke brings to Exopharm his extensive experience providing corporate advisory services for companies listed on the Australian Securities Exchange (ASX) across a variety of industries, with a particular focus on growth opportunities in the Biotechnology, Technology, Industrial and Resource industries, providing them with advice on business models & strategy, structuring of pre-IPO and IPO fund raisings, reverse takeovers, capital raisings, mergers and acquisitions, investor relations and general equity capital markets advice. Clarke holds a Bachelor of Commerce degree from the University of Western Australia and is a Member of the Australian Institute of Company Directors (AICD).